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Abstract  
Epigenetic processes have been implicated in addiction; yet, it remains unclear whether these 
represent a risk factor and/or a consequence of substance use. Here, we conducted the first 
genome-wide, longitudinal study to investigate whether DNA methylation patterns in early 
life prospectively associate with substance use in adolescence. The sample comprised of 244 
youth (51% female) from the Avon Longitudinal Study of Parents and Children (ALSPAC), 
with repeated assessments of DNA methylation (Illumina 450k array; cord blood at birth, 
whole blood at age 7) and substance use (tobacco, alcohol and cannabis use; age 14-18). We 
found that, at birth, epigenetic variation across a tightly interconnected genetic network (n = 
65 loci; q<0.05) associated with greater levels of substance use during adolescence, as well as 
an earlier age of onset amongst users. Associations were specific to the neonatal period and 
not observed at age 7. Key annotated genes included PACSIN1, NEUROD4 and NTRK2, 
implicated in neurodevelopmental processes. Several of the identified loci were associated 
with known mQTLs, and consequently likely to be under significant genetic control. 
Collectively, these 65 loci were also found to partially mediate the effect of prenatal maternal 
tobacco smoking on adolescent substance use. Together, findings lend novel insights into 
epigenetic correlates of substance use, highlight birth as a potentially sensitive window of 
biological vulnerability and provide preliminary evidence of an indirect epigenetic pathway 
linking prenatal tobacco exposure and adolescent substance use. 
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Introduction  
Substance abuse is a major public health concern that incurs heavy costs to individuals, their 
families and wider society. Collectively, it is estimated that one in ten of all fatalities result 
from harmful use of alcohol, tobacco and illicit drugs, representing one of the leading 
preventable causes of death worldwide (1). In addition, substance abuse is associated with a 
range of negative outcomes that compromise quality of life and long-term productivity, 
including psychiatric illness, disability, criminality and unemployment (2, 3). Consequently, 
a key challenge for research is to identify factors that drive individual susceptibility to 
substance abuse, in order to inform effective prevention and early intervention strategies (4).  
 Like most complex phenotypes, substance abuse results from a dynamic interplay of 
genetic and environmental influences. Studies have shown that the heritability of substance 
use disorders is moderate to high (~49-70%; 5), and that this genetic vulnerability interacts 
with environmental risk exposure. Indeed, epidemiological studies have identified a number 
of pre- and postnatal factors associated with substance abuse risk, including substance 
exposure during pregnancy, parental psychopathology and criminality, low socioeconomic 
status, childhood maltreatment and affiliation with delinquent peers (6). However, the 
biological mechanisms through which these effects are mediated are poorly understood.   
 In recent years, epigenetic processes that regulate gene expression (7) have emerged as 
a potential mechanism of interest. One of these processes, DNA methylation (DNAm), has 
received increasing attention. DNAm modulates transcription via to the addition of a methyl 
group to DNA base pairs, primarily in the context of cytosine-guanine (CpG) dinucleotides 
(7). Studies have shown that (i) DNAm is affected by genetic variability, as demonstrated by 
the discovery of a large number of methylation quantitative trait loci  (mQTLs; 8, 9); (ii) 
DNAm is also sensitive to pre- and postnatal environmental influences, including nutritional, 
chemical, and psychosocial factors (e.g. prenatal tobacco exposure; 10, 11); and (iii) aberrant 
patterns of DNAm have been linked to a wide range of physical and psychiatric disorders, 
including addiction (12). For example, animal studies have shown that repeated drug 
administration (e.g. alcohol, cocaine) can lead to DNAm changes in reward-related regions of 
the brain (e.g. striatum; 13). In turn, these changes can influence the expression of genes 
involved in synaptic plasticity and memory consolidation, driving neuroadaptations that 
underlie the onset and persistence of addictive behaviors (14). Importantly, drug-induced 
epigenetic changes have been found to occur as early as gestation (12). For example, a recent 
study in mice reported an epigenetically-mediated effect of early nicotine exposure on pup’s 
neural structure and behavior, which persisted into adulthood (15). So far, studies in humans 
have provided initial support for animal findings, reporting methylomic differences between 
substance abusers and drug-free controls across several tissue types and substances (12, 16). 
 Despite these promising findings, current research in humans has been limited in four 
key ways (17). First, the vast majority of studies have examined adult samples already 
exposed to substances. As a result, it has not been possible to establish whether altered 
DNAm patterns are a risk factor for and/or consequence of substance use. Disentangling 
these associations is essential in order to better delineate the role of epigenetic mechanisms in 
addiction risk and to enable the identification of novel therapeutic targets. Second, because 
existing studies have typically included DNAm data at a single time point, it is unclear 
whether epigenetic effects may be observable across time or only during specific 
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developmental periods. This is particularly relevant given that DNAm has been shown to be 
highly dynamic across the lifespan, enabling cells to respond to changing internal and 
external inputs (18). As such, clarifying how DNAm associates with substance use over time 
may provide important insights into windows of biological vulnerability. Third, little is 
known about what genetic and environmental factors may underlie variability in DNAm 
patterns associated with substance use. Characterizing these potential influences may not only 
offer valuable opportunities for preventative intervention, but also make it possible to test the 
role of the epigenome as a potential mediator in the link between risk exposure and later 
substance use. Finally, existing studies have primarily focused on one type of substance at a 
time. Although substance-specific risk factors have been identified, evidence from both 
genetically-informative and epidemiological studies indicate that substance use risk across 
drug classes is largely accounted for by a common underlying liability dimension (5, 19). 
Consequently, examining epigenetic markers common to multiple substances, in addition to 
substance-specific markers, may help shed further light into the biological basis of substance 
use liability.   
 To address these gaps in the literature, we conducted the first genome-wide, prospective 
study to examine associations between DNAm in early life (i.e. collected at repeated time-
points pre-substance use initiation; birth, age 7) and substance use in adolescence (measured 
as a latent factor spanning tobacco, cannabis and alcohol use). Our aim was to address the 
following key questions: 
1. Are DNAm patterns at birth prospectively associated with adolescent substance use?  
2. Are these associations stable across early childhood (birth to age 7)?   
3. Do the identified DNAm markers associate with genetic and environmental influences?  
 
Materials and Methods 
Participants 
The Epigenetic Pathways to Conduct Problems Study consists of a subsample of youth 
(n=339) drawn from the Avon Longitudinal Study of Parents and Children  (ALSPAC) who 
(i) have repeated measures of DNAm and (ii) follow previously established trajectories of 
conduct problems (4-13 years; 20). Only youth who had complete substance use ratings (age 
14-18) as well as epigenetic data at birth and age 7 (n = 244, 54% female) were included in 
the present study.  ALSPAC is an ongoing epidemiological study of children born between 
1991-92 from 14,541 women residing in Avon, UK. Of these initial pregnancies, there was a 
total of 14,676 fetuses, resulting in 14,062 live births and 13,988 children who were alive at 1 
year of age (21). When compared to 1991 National Census Data, the ALSPAC sample was 
found to be broadly similar to the UK population as a whole (22). Informed consent was 
obtained from all ALSPAC participants and ethical approval was obtained from the ALSPAC 
Law and Ethics Committee and the Local Research Ethics Committees. Please note that the 
study website contains details of all the data that is available through a fully searchable data 
dictionary: http://www.bris.ac.uk/alspac/researchers/data-access/data-dictionary/.  
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Measures 
Adolescent substance use  
Substance use was assessed via self-report ratings of tobacco and cannabis use (age 14, 16 
and 18 using frequency items ranging from ‘never’ to ‘daily’), as well as alcohol use (age 16 
and 18 using the 10- item Alcohol Use Disorders Identification Test; 23). Confirmatory factor 
analysis was used to extract (i) three first-order factors of tobacco, cannabis and alcohol use, 
accounting for shared variance across time points for each of these substances; and (ii) a 
single second-order factor of substance use, accounting for shared variance between 
substances and across time. The factor model showed adequate fit: χ2 (18)=49.55; p<.01; 
comparative fit index (CFI)=.91; Tucker-Lewis index (TLI)=.86; root mean square error of 
approximation (RMSEA)=.08, 90% CIs=.05, .10; with standardized loadings ranging from 
.58 to .96 (see Supplementary Figure 1).  
DNA methylation data 
500ng high molecular weight genomic DNA from blood (cord at birth, whole at age 7) was 
bisulfite-converted using the EZ-DNA methylation kit (Zymo Research, Orange, CA, USA). 
DNAm was quantified using the Illumina HumanMethylation450 BeadChip (Illumina, USA) 
with arrays scanned using an Illumina iScan (software version 3.3.28). Initial data quality 
control was conducted using GenomeStudio (version 2011.1) to determine the status of 
staining, hybridization, target removal, bisulfite conversion, specificity, non-polymorphic and 
negative controls. Samples that survived this stage were quantile normalised using the dasen 
function within the wateRmelon 1.0.3 package (24) in R and batch corrected using the 
ComBat package (25). Probes were removed if they were cross-reactive, used for sample 
identification on the array, or had a SNP at the single base extension with a minor allele 
frequency larger than 5% (i.e. common polymorphisms), leaving a total of 413,510 probes 
(26, 27). DNAm levels are indexed by beta values (ratio of: methylated signal/ methylated + 
unmethylated signal). 
Prenatal environmental risks 
We included prenatal risks that have been previously linked to adolescent substance use, 
including maternal prenatal smoking, alcohol use and exposure to stressful events (6). 
Maternal smoking and alcohol use during the first trimester of pregnancy were measured via 
maternal ratings, using a yes/no binary variable for smoking (for biological validation see the 
results section), and a 4-point scale for alcohol use (‘never’ to ‘daily’). With regards to stress 
exposure, we included cumulative risk scores of prenatal (18 to 32 weeks) adversity covering 
the following four domains: (i) life events (e.g. death in family, accident); (ii) contextual risks 
(e.g. poor housing, financial problems); (iii) parental risks (e.g. psychopathology, criminal 
behaviour); and (iv) interpersonal risks (e.g. partner abuse, family conflict). These 
cumulative risk scores were estimated using confirmatory factor analysis based on maternal 
reports, as described elsewhere (28). 
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Data Analysis 
Analyses were performed in R (version 3.0.1; 29) and Mplus (version 6.1.1; 30), adjusting for 
sex and cell-type proportions (CD8 T lymphocytes, CD4 T lymphocytes, natural killer cells, 
B lymphocytes, monocytes), estimated using the reference-based approach detailed in 
Houseman et al (31). 
Step 1: Are DNAm patterns at birth associated with adolescent substance use? 
Genome-wide association analyses between DNAm at birth and substance use were 
performed using the IMA package (32). Differentially methylated probes (DMPs) passing a 
False Discovery Rate (FDR) correction of q<0.05 were considered significant. These DMPs 
were then uploaded to the UCSC genome browser (GRCh37/hg19 assembly; 33) to explore 
their potential functional relevance, by comparing their genomic location to that of key 
regulatory elements recorded in the Encyclopedia of DNA Elements (ENCODE) database 
(http://genome.ucsc.edu/ENCODE/), including (i) transcription factor binding sites (data 
generated on 161 transcription factors in 91 cell types via ChIP-seq); (ii) DNase I 
hypersensitivity clusters (based on data from 125 cell types), and (iii) histone marks (only 
relevant cell lines examined, including blood [GM12878, K562] and umbilical vein 
endothelial [HUVEC] cells).  
 Genes to which DMPs were annotated were then examined to identify (i) underlying 
genetic networks, using the GeneMANIA bioinformatics software, which is based on known 
genetic and physical interactions, shared protein domains as well as co-expression data 
(http://www.genemania.org; see Supplementary Table 1); and (ii) enriched biological 
pathways, by using an optimized gene ontology method that controls for a range of potential 
confounds, including background probe distribution and gene size (Supplementary Table 1). 
 As a supplement to the probe-level analysis, we also used the Comb-p application 
within Python (34) with default settings (p threshold: 1.00E-04; sliding window size: 500bp), 
to identify wider differentially methylated regions based on spatially-correlated p-values. 
Step 2: Are these associations stable across early childhood (i.e. birth to age 7)?   
Given that DNAm is temporally dynamic (18) – particularly in early development (9) – 
markers identified at one time point may not necessary continue to be associated with 
substance use at other time points. To test this, we examined whether DMPs identified in 
Step 1 (i.e. birth) were also significantly associated with adolescent substance use at age 7 
(i.e. follow-forward approach; FDR-corrected q<0.05).  
Step 3: Do these markers relate to genetic and environmental influences?   
As a last step, we investigated potential genetic and environmental factors that may influence 
DNAm levels of the identified DMPs. Given that our sample was underpowered to directly 
examine genetic polymorphisms (i.e. SNPs) affecting DNAm, we used the ALSPAC-derived 
mQTLdb resource (http://www.mqtldb.org/) to search for known methylation quantitative 
trait loci (mQTLs) associated with our DMPs (see Supplementary Table 1 for further 
details). Potential environmental influences were examined next by testing associations 
between prenatal exposures and DMPs. Because of the large number of DMPs identified, we 
grouped these into a single, cumulative DNAm risk score to minimize multiple testing burden. 
Specifically, we applied a method typically used for polygenic risk scores (35), where we 
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multiplied the methylation values of our DMPs by their respective standardized regression 
betas (i.e. weights), and then summed these together into a DNAm risk score. This approach 
enabled us to reduce the volume of our methylation data, while the use of weights ensured 
that DMPs maintained their relative predictive importance (i.e. as opposed to alternative 
approaches, e.g. averaging DNAm levels across DMPs). Once calculated, we examined 
associations between this DNAm risk score and prenatal exposures, using Pearson’s bivariate 
correlations. Significant prenatal risks (q<0.05) were then incorporated into a single path 
analytic model in Mplus (maximum likelihood estimation), together with the DNAm risk 
score and the substance use factor, in order to test for indirect effects. Associations in the 
model were considered significant if they survived bootstrapped confidence intervals (10,000 
times; 36). Significant paths (i.e. prental risks  DNAm  substance use) were tested for an 
indirect effect using bootstrapped model constraint statements.  
Code availability 
Computer code used in our analyses is available from the authors upon request. 
 
Results  
Epigenome-wide association analysis at birth 
At birth, 65 probes prospectively associated with adolescent substance use after genome-wide 
correction (q<0.05; Table 1; Figure 1A). Of these DMPs, 33 were ‘hypomethylated’ (i.e. 
lower DNAm associating with higher substance use), while the other 32 were 
‘hypermethylated’ (i.e. higher DNAm associating with higher substance use). Overall, DMPs 
were most frequently located in the gene body (40%) or promoter region near the 
transcription start site (30%; see Supplementary Table 2). DNAm levels were significantly 
interrelated across the majority of DMPs (76% of correlations = q<0.05; rmax=0.58; rmin= -
0.52; rabsolute average =0.20; see Supplementary Table 3).  The most significant probe, 
cg04941418 (p = 1.10E-08; q = 0.005, Figure 1B), is located in PACSIN1, a developmentally 
regulated gene that plays an important role in synaptic neurotransmission, axonal growth and 
dendritic branching (37, 38). Other annotated genes in the table include (i) SHC2 
(cg02290110) and NTRK2 (cg01009697), both implicated in neuronal neurotrophin-activated 
Trk receptor signaling (39, 40), (ii) CLSTN1 (cg07395930), involved in calcium-mediated 
postsynaptic signals, and (iii) NEUROD4 (cg20056324), involved in neural differentiation. 
DMPs were then uploaded in Genome Browser for functional characterization, based on 
ENCODE data on regulatory elements. All DMPs overlapped with histone marks; 62% (n = 
40) coincided with transcription factor binding sites; and 57% (n = 37) were located within 
DNAse I hypersensitive clusters. Overall, 48% (n = 31) of DMPs were mapped to all three 
regulatory elements (Supplementary Table 4).  
DMPs were annotated to a total of 60 genes, which were examined further to identify 
underlying genetic networks and enriched biological pathways. Based on GeneMANIA 
analysis, 57 of the 60 genes were connected to form a compact cluster network (Figure 1C). 
Our gene ontology analysis also indicated that these genes are involved in a range of 
biological processes, including regulation of JAK-STAT cascade, vasoconstriction, cytokine-
mediated signaling and axonogenesis (2.30E-18<p<3.37E-03; Figure 1D). Of note, enriched 
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cellular components included axon part, postsynaptic membrane and dendritic spine (2.94E-
04<p<3.09E-03; for the full list of GO terms, see Supplementary Table 5).  
Results from the Comb-p analysis indicated that there were no significant 
differentially methylated regions after genome-wide correction. 
**************************** Table 1 & Figure 1 **************************** 
Follow-forward at age 7 
None of the DMPs identified at birth continued to prospectively associate with adolescent 
substance use by age 7, after multiple correction (i.e. q>0.05; Supplementary Table 6). Two 
DMPs showed nominal associations (cg02404636 [SFI1]: StdB =0.21, p=0.001; cg20056324 
[NEUROD4]: StdB=0.13, p=0.05), both following the same direction of effects observed at 
birth. Given this lack of temporal stability, we proceeded to test, for each DMP, how much 
DNAm levels at birth correlated with those at age 7 (i.e. autocorrelation). We found that only 
12 DMPs (18%) showed an autocorrelation significant at p<0.05, 11 of which were in the 
positive direction (across all DMPs: rmax=0.67; rmin= -0.13; rabsolute average=0.07). Interestingly, 
however, the pattern of intercorrelations across DMPs at age 7 resembled that observed at 
birth (Supplementary Figure 2). In other words, while DMPs typically did not correlate 
with themselves over time, the way in which they correlated with each-other within time 
points was very similar, potentially reflecting a similar underlying co-methylation network.  
Genetic and environmental influences 
The 65 DMPs identified at birth were carried forward to explore associations with potential 
genetic and environmental influences. Based on mQTLdb search, we found that five of the 
DMPs were associated with known mQTLs (ncis=4; ntrans=1), suggesting that DNAm levels 
across these sites are likely to be under considerable genetic control (Supplementary Table 
4). Of note, temporal stability of these DMPs was stronger (raverage=0.25) than the average 
across all DMPs noted above, consistent with what has previously been observed at the 
genome-wide level (9). With regards to environmental influences, we found that three 
prenatal exposures significantly correlated with DNAm (measured as a cumulative risk score 
comprising of all DMPs) – maternal tobacco smoking, maternal risks and contextual risks 
(Table 2). To test for indirect effects, we estimated a path analytic model (Figure 2A) that 
included these three prenatal exposures, the cumulative DNAm risk score, and the adolescent 
substance use outcome. Maternal smoking was the only prenatal factor to uniquely associate 
with higher cumulative DNAm risk (over and above other exposures), which in turn 
associated with higher substance use in adolescence (Figure 2B). Analysis of this pathway 
indicated a significant indirect effect of maternal smoking on substance use, via cumulative 
DNAm risk (unstandardized b=0.19, s.e.=0.07, p=0.01, bootstrapped 95% CI = 0.05-0.37).  
To minimize the possibility that associations with prenatal exposures may simply reflect 
genetic confounding, we reran analyses using a cumulative DNAm risk score that did not 
include any of the DMPs associated with mQTLs (i.e. 5 probes removed). This score was 
highly correlated with the original score (r = 0.99; p = 3.88E-252) and findings remained 
consistent.  
 
**************************** Table 2 & Figure 2 **************************** 
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Follow-up analyses 
PACSIN1: Relevance to the brain 
PACSIN1cg04941418 emerged as the top DMP at birth to associate with adolescent substance 
use. Given that our DNAm data was extracted from peripheral blood, we used the Genotype-
Tissue Expression project portal (GTEx; http://www.gtexportal.org/home/; 41) and the 
EMBL-EBI Expression Atlas (https://www.ebi.ac.uk/gxa/home/; 42) to assess PACSIN1 
expression across tissues. PACSIN1 was found to be most highly expressed in brain tissue, 
including regions implicated in drug-seeking behavior and addiction risk, such as the 
prefrontal cortex, nucleus accumbens, amygdala, and hippocampus (Supplementary Figure 
3).  We then used the BrainCloud tool (http://braincloud.jhmi.edu/plots/; 43), to trace the 
developmental course of PACSIN1 expression across the lifespan (fetal – age 80), based on 
postmortem prefrontal cortex tissue from 269 healthy subjects. The resulting plot showed that 
the most dramatic change in expression levels occurs during the neonatal period, bridging 
lower expression levels during fetal development with a higher, stable trajectory of 
expression from around three months of age onward (Supplementary Figure 3).  
Age of substance use onset 
65 DMPs at birth prospectively associated with substance use severity in adolescence. As a 
sensitivity analysis, we additionally tested whether these DMPs also associated with age of 
onset amongst substance users. Based on three items that combined self-report data across 
age 16 and 18, we found that, within youth who endorsed using substances, higher 
cumulative DNAm risk correlated with lower reported age when first ‘smoked whole 
cigarette’ (r = -0.19, p = 0.03, nendorse = 129), ‘tried cannabis’(r = -0.36, p = 3.40E-04, nendorse 
= 93), and ‘had whole alcoholic drink’(r = -0.23, p = 0.001, nendorse = 195), respectively. For 
data on frequencies, correlations and details about how the items were created, see 
Supplementary Table 7.   
Indirect effects for specific substances 
We found a significant indirect effect of prenatal tobacco smoking on adolescent substance 
use, via cumulative DNAm risk. Here, we wanted to clarify whether this indirect effect was 
observed across all substances or only specific ones (e.g. adolescent tobacco use). To this 
end, we reran the path analysis with the three first-order factors of tobacco, cannabis and 
alcohol use (see Supplementary Figure 4). Indirect effects were significant across all three 
substance types (tobacco: b = 0.31, s.e. = 0.12, p= 0.01, bootstrapped 95% CI = 0.09-0.59; 
cannabis: b = 0.71, s.e. = 0.29, p= 0.01, bootstrapped 95% CI = 0.22-1.34; alcohol: b = 0.14, 
s.e. = 0.06, p= 0.03, bootstrapped 95% CI = 0.04-0.30). Because the first-order factor of 
cannabis use contained one outlier (i.e. >3 s.d. from the mean), the analysis was also rerun 
with winsorized data for this score and results remained consistent.  
Biological validation of prenatal maternal smoking 
Finally, to ensure the validity of our measure of prenatal smoking – which was derived from 
a single yes (n = 48) /no (n = 213) item reported by mothers – we ran an epigenome-wide 
analysis with prenatal smoking predicting neonatal DNAm. As expected, the top 
differentially-methylated locus was cg05575921 (AHRR; p= 6.96e-16; q =2.88E-10, see 
Supplementary Table 8), a well-established, sensitive and specific biomarker of tobacco 
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exposure (10, 11, 44). Of note, there was no overlap between the maternal smoking and 
adolescent substance use DMPs. 
 
Discussion  
The aim of this study was to characterize DNA methylation patterns prospectively associated 
with substance use risk, using longitudinal data spanning gestation to adolescence. We 
highlight here three key findings: (i) epigenetic variation across 65 loci at birth associated 
with higher tobacco, cannabis and alcohol use in adolescence, as well as an earlier age of 
substance use onset; (ii) these effects were specific to the neonatal period and not observed in 
mid-childhood; and (iii) several of the identified loci were associated with known genetic 
mQTLs, and all, collectively, mediated the effect of prenatal tobacco smoking on adolescent 
substance use. These findings lend novel insights into epigenetic predictors of substance use, 
highlight birth as a potentially sensitive window of biological vulnerability and provide 
preliminary support for the role of DNAm as an indirect pathway linking prenatal exposures 
to adolescent behavioral outcomes. 
Epigenetic variation at birth associates with substance use in adolescence 
While the impact of substance use on DNAm has been repeatedly documented (12), less is 
known about the extent to which DNAm may confer risk for substance use, as existing 
studies have typically focused on adults already exposed to substances. To our knowledge, 
this is the first study to address this gap by examining DNA collected prior to substance use 
initiation. Furthermore, the use of a latent factor score comprising of tobacco, cannabis and 
alcohol use enabled us to examine the potential role of methylomic variation in broader 
substance use liability. Based on genome-wide analyses, we found that epigenetic variation 
across 65 loci at birth associated with higher substance use 14-18 years later, as well as an 
earlier age of onset amongst substance users. These loci were annotated to genes that, 
together, formed a compact underlying genetic network and were enriched for a range of 
biological pathways, including neural processes (e.g. axonogenesis, synaptic transport) and 
cellular components (e.g. axon, dendritic spine, post-synaptic membrane). The most 
differentially methylated locus was annotated to PACSIN1, a developmentally-modulated 
gene that plays an important role glutamate neurotransmission, axonal growth, dendritic 
branching and synaptic plasticity (45) and that is highly expressed in brain tissue (37, 38), 
including regions implicated in drug-seeking behavior and addiction risk (e.g. nucleus 
accumbens; frontal cortex, amygdala and hippocampus; 46). Other key annotated genes also 
implicated in early brain development included NEUROD4, involved in neuronal 
differentiation, and NTRK2, a Trk receptor for multiple neurodevelopmental genes, including 
Brain-derived Neurotrophic Factor, Neutrophin 4 and Nerve Growth Factor (40).  
The neonatal period as a potential window of biological vulnerability  
The inclusion of repeated DNAm measures enabled us to test the stability of epigenetic 
effects during childhood. We found that none of the loci identified at birth continued to 
predict substance use by age 7 (after multiple correction). This specificity of effects around 
birth is consistent with previous studies from our group examining longitudinal associations 
between DNAm and developmental outcomes (28, 47, 48). Findings are also consistent with 
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a recent study based on the ALSPAC sample that reported low genome-wide continuity in 
DNAm patterns over time (9), especially when comparing birth to other time points. A 
number of factors may drive the temporal differences observed. First, findings may reflect 
tissue-specific DNAm patterns, as data was extracted from two different blood sources (cord 
blood at birth vs whole blood at age 7). Second, differences may reflect the specific timing of 
environmental influences, whereby methylation patterns at birth may be a more reliable 
proxy for intra-uterine risk exposures and associated perturbations in fetal development (49), 
compared to age 7. Third, the neonatal period may represent a particularly sensitive window 
of biological vulnerability to future substance use.  For example, epigenetic patterns at birth 
may trigger downstream developmental consequences resulting in enduring individual 
differences (e.g. in neural networks underlying drug-seeking behavior and addiction; 12, 15), 
without the epigenetic signature being maintained over time (18). Given that we still know 
little about the role of tissue differences, environmental influences and developmental 
processes on DNAm (50), the above explanations are inevitably speculative and will 
necessitate further investigation.  
Genetic and environmental influences on DNAm patterns associated with substance use 
The identification of neonatal DNAm patterns associated with adolescent substance use raises 
questions about what kind of factors may drive this methylomic variation in the first place. 
Evidence suggests that DNAm patterns (8, 10) – like substance use liability (5, 6) – reflect 
the influence of both genetic and environmental factors. Based on data from mQTLdb (9), we 
found that five of our 65 DMPs were associated with known mQTLs, suggesting that they 
may be considerably influenced by genetic structure. While these associations point to 
potentially large genetic effects on a relatively small number of our DMPs, it is important to 
note that the heritability of DNAm patterns is greater than what can currently be explained 
using known mQTLs (9). As such, genetic effects on our other DMPs cannot be ruled out, 
especially the presence of polygenic effects. With regards to environmental influences, we 
found that three prenatal factors were associated with cumulative DNAm risk at birth (i.e. 
comprising all DMPs): maternal tobacco smoking (measured in the first trimester), maternal 
risks (e.g. psychopathology and criminal behaviour), and contextual risks (e.g. poor housing, 
financial problems). Associations remained consistent after removing any mQTL-related 
DMP from our DNAm risk score to minimize genetic confounding. These findings support 
the presence of both genetic and environmental influences on substance-use related DNAm 
patterns. It is important to note, however, that because associations were based on 
correlational analyses, they should be interpreted with caution and considered more as well-
grounded hypotheses for further examination in larger longitudinal studies. 
 
DNAm as an indirect pathway linking prenatal smoking to adolescent substance use 
We found that one prenatal exposure – maternal tobacco smoking – uniquely associated with 
substance use over and above other exposures, and that this association was partially 
mediated by cumulative DNAm risk at birth. Importantly, this indirect effect was observed 
across all three substance types (i.e. not just tobacco use, but also cannabis and alcohol use) – 
pointing to a potential link between prenatal tobacco exposure and broader substance use 
liability. To our knowledge, this is the first example in humans of an indirect effect of 
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prenatal exposures on substance-related outcomes via DNAm, consistent with recent work 
reported in animals (15). However, due to the correlational nature of the analyses, such 
evidence should be considered preliminary and in need of rigorous assessment using 
advanced causal inference methods (e.g. two-step Mendelian randomization; 51, 52). In 
particular, further work will be needed to trace the specific biological pathways through 
which this indirect effect may be expressed. For example, experimental studies have shown 
that prenatal nicotine exposure causes neuromorphological changes (e.g. dendritic branching, 
axonal growth, spine density) in brain circuits underlying motivation, learning and reward-
processing, which in turn confer latent vulnerability for substance use and other externalizing 
problems (e.g. hyperactivity, conduct problems; 15, 53, 54). As such, it will be interest to test 
whether the observed effect of prenatal nicotine exposure on substance use may be expressed 
via epigenetically-modulated changes in neural development, organization and structure. This 
will also require a more comprehensive investigation of DNAm in the context of other 
epigenetic processes, which have also been implicated in substance use and addiction (e.g. 
histone modifications and microRNAs, see 14 for a review). 
Limitations and future directions 
Findings should be interpreted in light of a number of limitations. First, the current study was 
based on a modestly sized population-based sample of youth. At present, ALSPAC is the 
only cohort, to our knowledge, that is prospective enough to enable the examination of 
neonatal DNAm patterns associated with adolescent substance use. Consequently, we were 
unable to replicate our results in an independent sample. In future, it will be important to test 
the robustness of findings using other epidemiological cohorts, as well as establishing the 
relevance of the identified markers in the development of more severe clinical phenotypes, 
including substance abuse and dependence. Second, findings were based on DNAm from 
peripheral samples; as such, more research will be needed to establish the relevance of the 
identified markers to brain function. Future studies incorporating imaging data will be 
important for establishing whether these markers associate with structural or functional 
alterations in addiction-relevant neural pathways (e.g. related to reward processing, impulse 
control, learning and memory), contributing to a more mechanistic understanding of the 
identified associations. Third, functional characterization of the DMPs was performed using 
ENCODE data, as we did not have access to RNA.  Integration of transcriptomic data will 
mark an important step toward establishing the downstream effects of the observed DNAm 
changes on gene expression. Fourth, despite the fact that we identified prospective 
associations between DNAm and substance use (i.e. DNAm collected before initiation of 
substance use), it is not possible to establish causality. Finally, the study focused exclusively 
on DNA methylation, and other epigenetic processes (e.g. histone modifications, 
microRNAs) are likely to be important in mediating the onset and consequences of addiction 
(14). 
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Conclusions 
The present findings lend novel insights into early epigenetic correlates of substance use, 
pinpointing specific markers for future interrogation. Evidence of temporally-specific effects 
points to birth as a potentially sensitive window of biological vulnerability, which may 
particularly benefit from intervention efforts. Findings also highlight prenatal smoking as an 
important prevention target, and contribute to a better understanding of the biological 
mechanisms through which tobacco exposure during pregnancy may increase risk for future 
substance use.  
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Figure legends 
Figure 1. Differentially methylated loci at birth associated with adolescent substance 
use. A. Manhattan plot showing genome-wide associations between DNA methylation at 
birth and later substance use (age 14-18). The dotted line represents the FDR-correction 
threshold (i.e. loci above the line are considered significant). B. Prospective association 
between the top differentially methylated locus at birth and later substance use. The X axis 
shows substance use factor scores while the Y axis represents beta methylation values, 
adjusted for sex and cell-type proportions. C.  Gene network analysis using GeneMANIA. 
Black circles represent genes (n =60) associated with the 65 probes found to be related to 
adolescent substance use in the genome-wide analysis at birth. Grey circles represent 
additional genes predicted by GeneMANIA based on genetic and physical interactions, 
shared protein domains as well as protein co-expression data. The gene network analysis 
demonstrates that, rather than being isolated, these genes clustered into a complex 
interconnected network. D. Significantly enriched biological processes (blue), molecular 
functions (purple) and cellular components (red), based on gene ontology (GO) analysis of 60 
genes annotated to probes that predict substance use at birth (n = 65; q < 0.05). Circles 
represent GO terms that survive FDR correction and contain at least one gene. The X axis 
represents -log(10) p values. The opacity of the circles indicates level of significance (darker 
= more significant). The size of the circles indicates the percentage of genes in our results for 
a given pathway compared to the total number of genes in the same pathway (i.e. larger size 
= larger %).  
 
Figure 2. Indirect effect of prenatal smoking on adolescent substance use via neonatal 
DNA methylation. A. Path analytic indirect effects model. Dotted arrowed lines indicate 
non-significant paths. Single arrowed lines indicate standardized path coefficients that 
survived bootstrap-corrected confidence intervals (i.e. significant path). Red arrows show 
significant indirect path. Population effect sizes are interpreted using the standardized 
estimates (Std. B) following Cohen’s guidelines: an effect of .10 is small effect, an effect of 
.24 is a medium effect, and an effect of .37 is a large effect. B. Graphical representation of 
the indirect effect, where prenatal smoking associates with higher cumulative DNA 
methylation risk at birth (top panel), which in turn associates with higher substance use in 
adolescence (bottom panel).  
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Table 1. DNA methylation loci at birth that prospectively associate with substance use in 
adolescence (n = 65, q<0.05) 
Probe Gene Chr Genomic location Position Std B P-value FDR (q-value) 
cg04941418 PACSIN1 6 5'UTR 34493129 -0.34 1.10E-08 0.005 
cg11074746 MEMO1 2 TSS1500 32236343 0.31 1.77E-07 0.02 
cg00335219 -- 16 -- 86012305 0.27 1.79E-07 0.02 
cg07395930 CLSTN1 1 Body 9791419 -0.31 3.84E-07 0.02 
cg01589998 FOXN4 12 Body 109729478 0.31 3.92E-07 0.02 
cg13978601 PPP2R4 9 Body 131905041 -0.31 4.10E-07 0.02 
cg23361356 SLC9A3 5 Body 508834 -0.31 4.17E-07 0.02 
cg27020216 SGEF 3 Body 153840347 0.29 8.35E-07 0.03 
cg14632140 LMO3 12 5'UTR 16758112 0.29 9.82E-07 0.03 
cg08080985 C9orf95 9 Body 77703079 0.30 1.07E-06 0.03 
cg20685020 ATP6V0B 1 5'UTR 44440676 0.30 1.34E-06 0.03 
cg25229198 ADAMTS6 5 Body 64660684 -0.30 1.38E-06 0.03 
cg05968179 USP6NL 10 Body 11505706 -0.29 1.42E-06 0.03 
cg01009697 NTRK2 9 TSS1500 87283470 0.29 1.56E-06 0.03 
cg19026817 -- 20 -- 56782259 -0.29 1.64E-06 0.03 
cg05116255 ANKRD30A 10 TSS1500 37413782 -0.29 1.85E-06 0.03 
cg04799664 NLRC5 16 5'UTR 57053850 -0.29 1.85E-06 0.03 
cg07746699 IFT140 16 TSS200 1662305 0.30 1.87E-06 0.03 
cg02290110 SHC2 19 TSS1500 461808 0.29 1.91E-06 0.03 
cg06951646 TRRAP 7 Body 98586548 -0.29 1.92E-06 0.03 
cg02052845 HGS 17 Body 79658835 -0.29 2.00E-06 0.03 
cg05033322 ATM 11 TSS1500 108093245 0.29 2.08E-06 0.03 
cg02404636 SFI1 22 TSS1500 31891804 0.29 2.10E-06 0.03 
cg05620865 AP3B1 5 Body 77588408 -0.29 2.22E-06 0.03 
cg14291256 MMP21 10 Body 127461065 -0.29 2.25E-06 0.03 
cg12593849 STX12 1 3'UTR 28150710 -0.29 2.31E-06 0.03 
cg10844884 ZNF22 10 Body 45498904 -0.29 2.32E-06 0.03 
cg27242945 CAV1 7 1stExon 116165134 0.28 2.35E-06 0.03 
cg13562386 TAGLN2 1 TSS1500 159895724 0.29 2.36E-06 0.03 
cg25767859 PKD1L1 7 Body 47859324 -0.29 2.37E-06 0.03 
cg12202228 FNDC3B 3 Body 171871829 -0.29 2.52E-06 0.03 
cg20056324 NEUROD4 12 TSS200 55413610 0.29 2.60E-06 0.03 
cg27122536 FOXF1 16 1stExon 86544658 0.29 2.67E-06 0.03 
cg14661886 PRRT3 3 TSS200 9994197 0.29 2.75E-06 0.03 
cg27596068 SERPINH1 11 TSS1500 75272301 -0.28 2.77E-06 0.03 
cg23088142 -- 3 -- 137531265 0.29 2.99E-06 0.03 
cg08625693 DLG3 X Body 69674126 -0.26 3.09E-06 0.03 
cg05463325 RAB4A 1 TSS1500 229406534 0.29 3.23E-06 0.04 
cg01894322 PPP1R1B 17 Body 37789575 -0.28 3.38E-06 0.04 
cg13138952 RPH3AL 17 Body 236013 -0.29 3.39E-06 0.04 
cg01338630 RASD2 22 3'UTR 35948166 -0.27 3.77E-06 0.04 
cg22409100 SLC8A1 2 TSS1500 40658918 0.14 4.01E-06 0.04 
cg24954684 CLIP1 12 TSS1500 122907641 0.27 4.08E-06 0.04 
cg22467567 IGFBP5 2 5'UTR 217559885 0.28 4.39E-06 0.04 
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cg25179876 NRP1 10 Body 33483109 -0.19 4.47E-06 0.04 
cg04388666 CCDC85C 14 TSS1500 100072073 0.28 4.61E-06 0.04 
cg13244417 TMTC4 13 TSS200 101327186 0.28 4.75E-06 0.04 
cg16661000 HAPLN3 15 5'UTR 89437710 0.27 4.81E-06 0.04 
cg00276455 -- 6 -- 54904638 -0.28 4.82E-06 0.04 
cg08261702 LOC728743 7 Body 150103112 0.25 5.02E-06 0.04 
cg05168344 LZTR1 22 Body 21340160 -0.28 5.07E-06 0.04 
cg02725795 FAM175A 4 Body 84405871 0.27 5.18E-06 0.04 
cg20336014 MGEA5 10 TSS200 103578255 0.27 5.49E-06 0.04 
cg26047334 TNS1 2 5'UTR 218785909 0.25 5.56E-06 0.04 
cg18769584 LZTFL1 3 3'UTR 45866619 -0.27 5.64E-06 0.04 
cg13083436 LUZP2 11 TSS200 24518414 0.28 5.74E-06 0.04 
cg23530543 HEPN1 11 TSS1500 124788414 -0.28 5.98E-06 0.04 
cg02957771 FBXO31 16 Body 87380349 -0.27 6.13E-06 0.04 
cg17396676 EPS15L1 19 TSS1500 16583990 -0.28 6.56E-06 0.04 
cg09278687 TBX6 16 Body 30100430 -0.28 6.91E-06 0.04 
cg20643362 C19orf12 19 1stExon 30206369 0.27 7.37E-06 0.04 
cg10395806 CTTN 11 Body 70280601 -0.28 7.43E-06 0.04 
cg00877150 BCOR X 5'UTR 39972039 -0.27 7.52E-06 0.04 
cg20319698 LRRFIP1 2 Body 238644099 -0.27 7.73E-06 0.04 
cg14712611 ANK2 4 5'UTR 113739379 0.27 7.74E-06 0.04 
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Table 2. Associations between prenatal exposures, cumulative DNAm risk at birth and adolescent substance use 
  Prenatal exposures 
  Maternal 
smoking  
  Maternal 
alcohol use 
  Maternal risks   Family risks   Contextual 
risks 
  Life Events 
  r p   r p   r p   r p   r p   r p 
Cumulative DNAm risk (birth) 0.20 1.21E-03   -0.07 0.28   0.15 0.01   -0.03 0.59   0.16 0.01   -0.07 0.26 
Substance use (age 14-18) 0.32 1.58E-07   -0.03 0.60   0.32 1.44E-07   0.09 0.15   0.28 4.33E-06   0.03 0.61 
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Figure 1. Differentially methylated loci at birth associated with adolescent substance use. 
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Figure 2. Indirect effect of prenatal smoking on adolescent substance use via neonatal DNA methylation. 
  
